Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

[This corrects the article DOI: 10.3389/fendo.2023.1214334.].

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 15; p. 1342543
Main Authors Zeng, Qingyue, Xu, Jiao, Mu, Xingyu, Shi, Yi, Fan, Hong, Li, Shuangqing
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.03.2024
Subjects
dual agonists
Endocrinology
glucagon-like peptide-1 receptor agonists
incretin based therapy
obesity
tirzepatide
type 2 diabetes
type 2 diabetes
tirzepatide
incretin based therapy
glucagon-like peptide-1 receptor agonists
obesity
dual agonists
Online AccessGet full text

Cover

More Information
Summary:[This corrects the article DOI: 10.3389/fendo.2023.1214334.].
Bibliography:corrigendum
SourceType-Other Sources-1
content type line 63
ObjectType-Correction/Retraction-1
These authors have contributed equally to this work and share first authorship
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2024.1342543